BRAINSTORM CELL THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.368 USD | -1.60% |
|
-2.52% | +34.80% |
| Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
| Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
Presenter SpeechChaim Lebovits (Executives)Good morning. I'm Chaim Lebovits, Executive Officer...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimerâs disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.368
USD
Average target price
2.5
USD
Spread / Average Target
+579.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.80% | 25.15M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +49.00% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- BCLI Stock
- News Brainstorm Cell Therapeutics Inc.
- Transcript : Brainstorm Cell Therapeutics Inc. - Shareholder/Analyst Call